Hichi Pharmaceutical, a Subsidiary of Beilu Pharmaceutical, Receives Approval for Iomeprol API

2025/08/13

hichi-pharmaceutical-a-subsidiary-of-beilu-pharmaceutical-receives-approval-for-iomeprol-api.png

Recently, Hichi Pharmaceutical's Iomeprol API has received the "Approval Notice for the Market Application of Chemical APIs" from the NMPA. This is another blockbuster product approved for market after Iohexol API, Ioversol API, Iopamidol API, and Iopromide API.

The approval of Iomeprol API will further enrich Hichi Pharmaceutical's varieties of API, driving steady growth in Hichi Pharmaceutical' API sales business, and continuing to enhance the company's market share in the contrast agent API field.

At the same time, this will also expand Beilu Pharmaceutical's depth and breadth in the "API and Formulation" integration within the contrast agent field, creating favorable conditions for the company to continue enhancing its competitive advantages and market share in the contrast agent field.

References

Related News

Beilu Pharmaceutical has been awarded "Beijing Advanced Unit of Adverse Drug Reactions Daily Monitoring" for 4 consecutive years.
August 4, 2022Recently, the Beijing Municipal Drug Administration and Beijing Municipal Health Commission issued the "notice on the outstanding Performance of units and individuals in the monitoring of adverse...view
Beilu was Awarded the Title of A-class enterprise for safety production
February 1, 2023Recently, Beijing Beilu Pharmaceutical Co., Ltd. was once again awarded the title of "Class A Unit for Safety Production" in Miyun Park of Zhongguancun District. The company has won this awa...view
Beilu Pharmaceutical Obtains Drug Registration Certificate for Pramoxine Hydrochloride Sustained Release Tablets
July 7, 2023Recently, Beilu Pharmaceutical received the Drug Registration Certificate for two sizes (0.375mg and 0.75mg) of Pramipexole Dihydrochloride Sustained-release Tablets (Pramipexole) from the National Me...view
Hichi Pharmaceutical, a Subsidiary of Beilu Pharmaceutical: Iopromide API Approved for Market Launch
July 2, 2025Recently, Hichi Pharmaceutical's Iopromide API has received the "Approval Notice for the Marketing Application of Chemical Raw Materials" from the National Medical Products Administratio...view
Beilu's Gadopentetate Dimeglumine Injection Passed the Quality and Efficacy of Generic Drugs Consistency Evaluation
July 27, 2021Recently, our company received the“Drug Supplementary Application Approval Notice”(Notice Number: 2021B02267, 2021B02268) for two specifications of Gadopentetate Dimeglumine Injection.view
Good News: Beilu Pharmaceutical won the 2020 National Adverse Drug Reactions Monitoring and Evaluation Excellent Unit
April 12, 2021On March 11th, the National Medical Products Administration (NMPA) issued the “Notice Recognizing Excellent Units in the National Adverse Drug Reactions Monitoring and Evaluation 2020”.view

Hichi Pharmaceutical, a Subsidiary of Beilu Pharmaceutical, Receives Approval for Iomeprol API

Beilu Pharmaceutical has been awarded "Beijing Advanced Unit of Adverse Drug Reactions Daily Monitoring" for 4 consecutive years.

Beilu was Awarded the Title of A-class enterprise for safety production

Beilu Pharmaceutical Obtains Drug Registration Certificate for Pramoxine Hydrochloride Sustained Release Tablets

Hichi Pharmaceutical, a Subsidiary of Beilu Pharmaceutical: Iopromide API Approved for Market Launch

Beilu's Gadopentetate Dimeglumine Injection Passed the Quality and Efficacy of Generic Drugs Consistency Evaluation

Good News: Beilu Pharmaceutical won the 2020 National Adverse Drug Reactions Monitoring and Evaluation Excellent Unit